Why the study?
Does nicardipine limit myocardial infarction and improve coronary collateral circulation in animal models of myocardial ischaemia?
Does nicardipine limit myocardial infarction and improve coronary collateral circulation in animal models of myocardial ischaemia?
Nicardipine demonstrates cardioprotective effects, including limitation of infarct size and improvement of collateral circulation, in preclinical models of myocardial infarction.
Preclinical findings only; leaves open any clinical role for nicardipine in limiting infarction or enhancing collaterals.
In a dog model of partial myocardial ischaemia, superimposed ST segment elevations in epicardial ECGs were inhibited by nicardipine over a cumulative i.v. dose range of 1-20 micrograms kg-1. Over the cumulative i.v. dose range of 0.5-166.5 micrograms kg-1, nicardipine had little overall effect on gross cardiac conduction, at spontaneous heart rate. Dogs that received oral 1-2 mg kg-1 nicardipine daily for 16 weeks and then survived 1 week occlusion of the left anterior descending coronary artery (LAD) developed a superior coronary collateral circulation compared with untreated animals. Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion. Compared with a group of completely untreated dogs, there was protection of the myocardium in the animals given nicardipine that survived 3 months occlusion of the LAD.
No takes yet. Share an insight, caveat, or question.
Alps et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: